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Advanced Breast Cancer (ABC) comprises both locally advanced
(LABC) and metastatic breast cancer (MBC) [1]. Although treatable,
it is remains an incurable disease with a median overall survival of
~2e3 years and a 5-year survival of only ~25% [2e4]. Some more
recent series seem to indicate an improvement in median overall
survival [5,6].
A recent comprehensive report [2] of the advances in this ﬁeld in
the last decade shows that progress has been slow in terms of
improved outcomes, quality of life, awareness and information
regarding ABC.
The level of evidence used to base many recommendations re-
mains low, and more and better designed trials are needed to
address clinically important questions. An improved understanding
of the biology of ABC, its heterogeneity, and of the mechanisms of
resistance to the different types of therapies is being acquired and it
is anticipated that the application of new technologies, such as next
generation sequencing, patient xenographs, systems biology, and
computer modelling, among others, will accelerate advances.
Aiming at providing clinically oriented guidelines on how to
best manage ABC, the 3rd International Consensus Conference for
Advanced Breast Cancer (ABC 3) took place in Lisbon, Portugal on
November 5the7th, 2015, bringing together over 1100 participants
from 84 countries, including health professionals, patient advo-
cates and journalists.
The ABC guidelines are developed as a joint effort from ESO
(European School of Oncology) and ESMO (European Society ofTable 1
Grading system [7].
Grade of recommendation/description Beneﬁt versus risk and burdens Methodolo
1A/strong recommendation,
high quality evidence
Beneﬁts clearly outweigh risk






Beneﬁts clearly outweigh risk







Beneﬁts clearly outweigh risk



















Beneﬁts closely balanced with
risks and burden
ObservatioMedical Oncology), and are endorsed by EUSOMA (European So-
ciety of Breast Cancer Specialists), ESTRO (European Society of Ra-
diation Oncology), UICC (Union for International Cancer Control),
SIS (Senologic International Society) and FLAM (Federation Latin-
oAmericana de Mastologia). There was also ofﬁcial representation
of ASCO (American Society of Clinical Oncology) in the consensus
panel. The ABC Conference was also organized under the auspices
of OECI (Organization of European Cancer Institutes), and with the
support of the BCRF (Breast Cancer Research Foundation) and the
Susan G Komen for the Cure.
The present article summarizes the guidelines developed at
ABC3 and is supported with the level of evidence, the percentage of
consensus reached at the Conference, and supporting references.Methodology
Prior to the ABC 3 Conference, a set of preliminary recommen-
dation statements on the management of ABC were prepared,
based on available published data and following the ESMO guide-
lines methodology. These recommendations were circulated to all
44 panel members by email for comments and corrections on
content and wording. A ﬁnal set of recommendations was pre-
sented, discussed and voted upon during the consensus session of
ABC 3. All panel members were instructed to vote on all questions,
with members with a potential conﬂict of interest or who did not
feel comfortable answering the question (e.g. due to lack of
expertise in a particular ﬁeld) instructed to vote ‘abstain’. Addi-
tional changes in the wording of statements were made during the
session. The statements related to management of side effects and
difﬁcult symptoms, included under the Supportive and Palliative
care section, were not voted on during the consensus session, but
discussed and unanimously agreed by email, and are considered to
have 100% agreement.
Supplementary Table S1, available at Annals of Oncology online,
lists all members of the ABC 3 consensus panel and their disclosures
of any relationships with the pharmaceutical industry that could be
perceived as a potential conﬂict of interest.gical quality of supporting evidence Implications
out important limitations or
ing evidence from
nal studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
important limitations
nt results, methodological ﬂaws,
r imprecise) or exceptionally
dence from observational studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
nal studies or case series Strong recommendation, but may change
when higher quality evidence becomes
available
out important limitations or
ing evidence from
nal studies
Weak recommendation, best action may
differ depending on circumstances or
patients' or societal values
important limitations
nt results, methodological ﬂaws,
r imprecise) or exceptionally strong
rom observational studies
Weak recommendation, best action may
differ depending on circumstances or
patients' or societal values
nal studies or case series Very weak recommendation, other
alternatives may be equally reasonable
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ABC2 [1] statements with only minor updates or with no updates
are listed in Table 2.Section 1: General recommendations.
Guideline statement
The ABC community strongly calls for clinical trials addressing important unanswered
and not just for regulatory purposes. Clinical trials should continue to be performed, e
treatment, providing real world performance of the therapy.
Every advanced breast cancer patient must have access to optimal cancer treatment and
highest standards of patient centered care, as deﬁned by:
Open communication between patients and their cancer care teams as a primary goal
Educating patients about treatment options and supportive care, through development
based information in a clear, culturally appropriate form.
Encouraging patients to be proactive in their care and to share decision-making with
Empowering patients to develop the capability of improving their own quality of life w
Always taking into account patient preferences, values and needs as essential to optim
We strongly recommend the use of objective scales, such as the ESMO Magnitude of C
Value Framework, to evaluate the real magnitude of beneﬁt provided by a new treatm
particularly in countries with limited resources.
The use of telemedicine oncology to help management of patients with ABC living in
option to consider when geographic distances are a problem and provided that issues
Strong consideration should be given to the use of validated PROMs (patient-reported ou
record the symptoms of disease and side effects of treatment experienced as a regular p
should be simple, and user-friendly to facilitate their use in clinical practice, and though
collection platform, e.g. tablets or smartphones. Systematic monitoring would facilitat
tients and their treatment teams by better characterizing the toxicities of all anticance
early intervention of supportive care services enhancing quality of life
As survival is improving in many patients with ABC, consideration of survivorship issu
care of these patients. Health professionals should therefore be ready to change and a
disease status, treatment adverse effects and quality of life, patients' priorities and life
Attention to chronic needs for home and family care, job and social requirements, sho
treatment planning and periodically updated.
ABC patients who desire to work or need towork for ﬁnancial reasons should have the o
and reasonable ﬂexibility in their working schedules to accommodate continuous trea
ABC patients with stable disease, being treated as a ‘chronic condition’, should have th
reconstruction.
In ABC patients with long-standing stable disease, screening breast imaging should be
Breast imaging should also be performed when there is a suspicion of loco-regional p
A biopsy (preferably providing histology) of a metastatic lesion should be performed,
diagnosis particularly when metastasis is diagnosed for the ﬁrst time.
Biological markers (especially HR and HER-2) should be reassessed at least once in the
feasible. Depending on the metastatic site (e.g. bone tissue), technical considerations n
pathologist.
If the results of tumour biology in the metastatic lesion differ from the primary tumor
result should be used for treatment-decision making. Since a clinical trial addressin
undertake, we recommend considering the use of targeted therapy (ET and/or anti-
are positive in at least one biopsy, regardless of timing.
To date, the removal of the primary tumor in patients with de novo stage IV breast can
prolongation of survival, with the possible exception of the subset of patients with bone
considered in selected patients, particularly to improve quality of life, always taking in
preferences. Of note, some studies suggest that surgery is only valuable if performed w
(e.g. complete removal of the disease) as in patients with early stage disease.
Additional prospective clinical trials evaluating the value of this approach, the best ca
currently ongoing
A small but very important subset of patients with ABC, for example those with oligo-m
metastatic disease that is highly sensitive to systemic therapy, can achieve complete r
A multimodal approach, including local-regional treatments with curative intent, shou
selected patients.
LoE, available level of evidence; consensus, percentage of panel members in agreementGeneral recommendations
The continuous increase in cancer care costs has inevitably led
to inequalities in access both between countries and within eachLoE Consensus
clinical questions in this setting,
ven after approval of a new
Expert opinion Voters: 43
Yes: 100%
supportive care according to the
.
and dissemination of evidence-
their health care providers.
ithin their cancer experience.
al cancer care.
Expert opinion Voters: 44
Yes: 100%
linical Beneﬁt Scale or the ASCO
ent and help prioritize funding,
Expert opinion Voters: 40
Yes: 87.5% (35)
Abstain: 5% (2)
remote places, is an important
of connectivity are solved.
Expert opinion Voters: 42
Yes: 92.8% (39)
Abstain: 4.7% (2)
tcomemeasures) for patients to
art of clinical care. These PROMs
t needs to be given to the easiest
e communication between pa-
r therapies. This would permit
1 C Voters: 39
Yes: 87.1% (34)
Abstain: 5.1% (2)
es should be part of the routine
dapt treatment strategies to
plans.
uld be incorporated in the
Expert opinion Voters: 40
Yes: 95% (38)
Abstain: 5% (2)
pportunity to do so, with needed
tment and hospital visits.
Expert opinion Voters: 42
Yes: 100%
e option to undergo breast Expert opinion Voters: 39
Yes: 82% (32)
Abstain: 7.6% (3)
an option. Expert opinion Voters: 40
Yes: 52.5% (21)
N: 47.5% (19)
rogression. Expert opinion Voters: 40
Yes: 100%
if easily accessible, to conﬁrm 1 B Voters: 43
Yes: 98% (42)
metastatic setting, if clinically
eed to be discussed with the
1 B Voters: 44
Yes: 98% (43)
, it is currently unknown which
g this issue is difﬁcult to
HER-2 therapy) when receptors
Expert opinion 87%
cer has not been associated with
only disease. However, it can be
to account the patient's
ith the same attention to detail
2 B Voters: 44
Yes: 70.4% (31)
ndidates and best timing are
etastatic disease or low volume
emission and a long survival.
Expert opinion Voters: 43
Yes: 91% (39)
ld be considered for these
with the statement.
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and important factors in treatment-decision making. Both ESMO
and ASCO have put considerable effort into the development of
validated objective scales aiming at evaluating the real magnitude
of beneﬁt provided by each new treatment, including efﬁcacy
measures (e.g. impact on DFS, OS or PFS) and toxicity/quality of life
measures. The ESMOMagnitude of Clinical Beneﬁt Scale [8] and the
ASCO Value Framework [9] are user-friendly tools that can greatly
assist decision-makers at the country and/or hospital level in the
difﬁcult decisions regarding approval and reimbursement.
The ABC3 experts also emphasize the responsibility of the aca-
demic and medical communities to advance the knowledge on
breast cancer and other relevant unanswered issues, by involve-
ment in clinical research aimed at addressing important clinical
questions, and not only in studies conducted for regulatory
purposes.
The importance of providing patients with full information in
appropriate, understandable and culturally sensitive way, as well as
involving them in sharing the decision-making regarding all as-
pects of their management has been repeatedly stressed in all ABC
guidelines [1,10]. A high standard of patient centred care includes
the following elements: appropriate information, good communi-
cation with health professionals, patient education, proactive
advocacy, sensitivity to the patient's preferences, values and needs,
and providing patients with the capabilities to improve their own
quality of life [11].
Although the overall survival of ABC has remained stable, for
some subtypes, and in particular HER-2-positive metastatic breast
cancer, prolonged survival, well beyond the median 2e3 years, has
become a frequent reality. For these long-term survivors, survi-
vorship issues which are speciﬁc for advanced cancer patients, have
emerged and need appropriate attention, research and manage-
ment. Work-related issues are central and solutions not easy to
implement. A recently published survey [12], found that approxi-
mately half of the women in employment had to change their work
situation due to ABC and that 37% of them had to give up work
temporarily or permanently. Due to these income problems and
those related to the cost of care, the same survey found that 56% of
ABC patients experienced a decline in household income as a result
of their disease. The ABC community strongly advocates for the
right of ABC patients to return or maintain their work, since a
substantial proportion of these patients are in their most produc-
tive years. Furthermore, in some countries, health coverage is
dependent on being employed. For that to occur, we need ﬂexibility
of working schedules, new communication technologies and
home-based work which the ABC community supports. In many
countries this may imply a change in the current labour-related
laws.
Survivorship issues also include the potential discussion of
breast reconstruction, in those cases where the metastatic disease
is either in complete remission or in a durable stable situation. No
consensus could be reached regarding the use of breast imaging to
follow-up the unaffected breast, but the experts agreed that im-
aging should be performed in case of suspicion of disease pro-
gression in the breast.Section 2: ABC important deﬁnitions.
Guideline statement
Oligo-metastatic disease is deﬁned as low volume metastatic disease with limited nu
lesions (up to ﬁve and not necessarily in the same organ), potentially amenable for
achieving a complete remission status.
Patients with multiple chronic conditions are deﬁned as patients with additional co
impaired renal or liver function, autoimmune disease) making it difﬁcult to accoun
extrapolations to develop speciﬁc recommendations for care.
LoE, available level of evidence; consensus, percentage of panel members in agreementRegarding the need to biopsy metastatic disease and re-evaluate
the common biomarkers, the ABC recommendations had only mi-
nor changes. There are situations where the need for a biopsy in the
metastatic setting is very clear, such as single lesions, history of two
or more malignancies, suspicion of benign histology or doubt be-
tween progression or post-treatment necrosis. There is also
consensus regarding the importance of such biopsy in situations
where when a change in biomarkers would impact the treatment
choice, which would mainly occur when biomarkers were negative
in the primary tumor. There is some controversy about the beneﬁts
of a biopsy in situations where there is no doubt about the nature of
the lesion(s) and where all receptors were positive in the primary
tumor, since the clinical implementation of new technologies such
as next generation sequencing for management decision-making is
not yet validated. However, the exact nature of a lesion is hard to
ascertain without the conﬁrmation by a biopsy as shown in some
retrospective and prospective studies [13e15]. There is also an
undisputable importance of collection of material for research
purposes, both ongoing and future.
Technical issues should be discussed with the breast patholo-
gist, in particular in case of bone biopsies with the inherent
decalciﬁcation problems, which may interfere with the biomarker
analysis [16,17], as experienced in Saﬁr01/UNICANCER trial [18]. For
that reason, decalciﬁcation using EDTA is recommended for bone
biopsies, when it is the only metastatic site [17]. Adding to the
complexity of this issue is the fact that negative biomarker results
may limit the eligibility for reimbursement of therapies dedicated
to speciﬁc subtypes, in some countries.
A number of prospective randomized trials have assessed or are
assessing the role of removing the primary tumor in patients with
de novometastatic disease. So far only two small studies have been
published/presented [19,20]. A subgroup analysis of the Turkish
study suggested a potential beneﬁt in patients with ER/PgRþ, HER-
2 negative, solitary bonemetastasis, who are younger than 55 years
of age, while patients withmultiple pulmonary and liver metastasis
did worse with an overall 3-year survival of 31% in the surgery
group versus 67% for the systemic therapy group [20]. In the Indian
trial, a decrease in distant progression-free survival was observed
in patients allocated to surgery. Results of larger, prospective
studies are awaited. Until then, the recommendation is to discuss
surgery on a case-by-case basis and importantly, only consider
surgery if it can be performed with a high quality procedure [21].
The deﬁnition of oligometastatic disease (see next section) has
been enlarged to encompass low volume metastatic disease, i.e.
limited number and size of metastatic lesions (up to ﬁve and not
necessarily in the same organ) and potentially amenable for local
treatment which is aimed at achieving a complete remission. The
development of minimally invasive surgical techniques and highly
conformal ablative radiotherapy allow for safe and effective abla-
tion of metastatic lesions in most locations. Although some retro-
spective studies have suggested that achieving a sustained
complete remission seems to be associated with a longer survival
[22], the true impact of these local-regional therapies on long-term
outcome remains unknown, and prospective and if possible ran-
domized trials are needed.LoE Consensus
mber and size of metastatic
local treatment, aimed at
Expert opinion  Voters: 36
 Yes: 78% (28)
 Abstain: 6% (2)
morbidities (e.g. cardiovascular,
t for all of the possible




Other ABC1 [10] and ABC2 [1] statements with only minor updates or with no updates.
Recommendations LoE % Consensus
ABC important deﬁnitions
Visceral crisis is deﬁned as severe organ dysfunction as assessed by signs and symptoms, laboratory studies, and
rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important
visceral compromise leading to a clinical indication for a more rapidly efﬁcacious therapy, particularly since another
treatment option at progression will probably not be possible.
Expert opinion 95
Primary endocrine resistance is deﬁned as: Relapse while on the ﬁrst 2 years of adjuvant ET, or PD within ﬁrst
6 months of 1st line ET for MBC, while on ET.
Expert opinion 67
Secondary (acquired) endocrine resistance is deﬁned as: Relapse while on adjuvant ET but after the ﬁrst 2 years,
or relapse within 12 months of completing adjuvant ET, or PD  6 months after initiating ET for MBC, while on ET.
Note: resistance is a continuum and these deﬁnitions help mainly clinical trials and not necessarily clinical practice
General statements
The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary
team (including but not restricted to medical, radiation, surgical oncologists, imaging experts, pathologists, gynecologists,
psycho-oncologists, social workers, nurses and palliative care specialists), is crucial.
Expert opinion 100
From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care,
and symptom-related interventions as a routine part of their care. The approach must be personalized to meet
the needs of the individual patient.
Expert opinion 100
Following a thorough assessment and conﬁrmation of MBC, the potential treatment goals of care should be
discussed. Patients should be told that MBC is incurable but treatable, and that some patients can live with
MBC for extended periods of time (many years in some circumstances).
Expert opinion 97
This conversation should be conducted in accessible language, respecting patient privacy and cultural differences,
and whenever possible, written information should be provided.
Patients (and their families, caregivers or support network, if the patient agrees) should be invited to participate
in the decision-making process at all times. When possible, patients should be encouraged to be accompanied
by persons who can support them and share treatment decisions (e.g. family members, caregivers, support network).
Expert opinion 100
There are few proven standards of care in ABC management. After appropriate informed consent, inclusion of
patients in well-designed, prospective, independent trials must be a priority whenever such trials are available
and the patient is willing to participate.
Expert opinion 100
The medical community is aware of the problems raised by the cost of ABC treatment. Balanced decisions should
be made in all instances; patients' well-being, length of life and preferences should always guide decisions.
Expert opinion 100
Specialized oncology nurses (if possible specialized breast nurses) should be part of the multidisciplinary team
managing ABC pts. In some countries this role may be played by a physician assistant or another trained
and specialized health care practitioner.
Expert opinion 92
All ABC patients should be offered comprehensive, culturally sensitive, up-to-date and easy to understand
information about their disease and its management.
1 B 97
The age of the patient should not be the sole reason to withhold effective therapy (in elderly patients) nor to
overtreat (in young patients). Age alone should not determine the intensity of treatment.
1 B 100
Assessment guidelines
Minimal staging workup for MBC includes a history and physical examination, hematology and biochemistry
tests, and imaging of chest, abdomen and bone.
2 C 67
Brain imaging should not be routinely performed in asymptomatic patients. This approach is applicable to all
patients with MBC including those patients with HER-2þ and/or TNBC MBC.
Expert opinion 94
The clinical value of tumor markers is not well established for diagnosis or follow-up after adjuvant therapy,
but their use is reasonable (if elevated) as an aid to evaluate response to treatment, particularly in patients
with non-measurable metastatic disease. A change in tumor markers alone should not be used to initiate
a change in treatment.
2 C 89
Evaluation of response to therapy should generally occur every 2e4 months for ET or after two to four cycles
for CT, depending on the dynamics of the disease, the location and extent of metastatic involvement,
and type of treatment.
Expert opinion 81
Imaging of target lesions may be sufﬁcient in many patients. In certain patients, such as those with indolent
disease, less frequent monitoring is acceptable.
Additional testing should be performed in a timely manner, irrespective of the planned intervals, if PD is suspected
or new symptoms appear. Thorough history and physical examination must always be performed.
Treatment general guidelines
Treatment choice should take into account at least these factors: HR and HER-2 status, previous therapies and
toxicities, disease-free interval, tumour burden (deﬁned as number and site of metastases), biological age,
performance status, co-morbidities (including organ dysfunctions), menopausal status (for ET), need for
a rapid disease/symptom control, socio-economic and psychological factors, available therapies in the
patient's country and patient preference.
Expert opinion 100
ERþ/HER-2 negative ABC
Endocrine treatment after CT (maintenance ET) to maintain beneﬁt is a reasonable option, although
this approach has not been assessed in randomized trials.
1 C 88
Concomitant CT þ ET has not shown a survival beneﬁt and should not be performed outside of a clinical trial. 1 B 100
Chemotherapy and biological therapy
Both combination and sequential single agent CT are reasonable options. Based on the available data, we
recommend sequential monotherapy as the preferred choice for MBC. Combination CT should be reserved for
patients with rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or
disease control
1 B 96
In the absence of medical contraindications or patient concerns, anthracycline or taxane based regimens, preferably
as single agents, would usually be considered as ﬁrst line CT for HER-2 negative MBC, in those patients who have
not received these regimens as (neo)adjuvant treatment and for whom chemotherapy is appropriate. Other
options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding
alopecia is a priority for the patient.
1 A 71
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Table 2 (continued )
Recommendations LoE % Consensus
In patients with taxane-naive and anthracycline-resistant MBC or with anthracycline maximum cumulative
dose or toxicity (i.e. cardiac) who are being considered for further CT, taxane-based therapy, preferably as
single agents, would usually be considered as treatment of choice. Other options are, however, available
and effective, such as capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient.
1 A 59
In patients pre-treated (in the adjuvant and/or metastatic setting) with an anthracycline and a taxane,
and who do not need combination CT, single agent capecitabine, vinorelbine or eribulin are the preferred
choices. Additional choices include gemcitabine, platinum agents, taxanes, and liposomal anthracyclines.
The decision should be individualized and take into account different toxicity proﬁles, previous exposure,
patient preferences, and country availability.
1 B 77
If given in the adjuvant setting, a taxane can be re-used as 1st line therapy, particularly if there has been at
least 1 year of disease-free survival.
1 A 92
Duration of each regimen and the number of regimens should be tailored to each individual patient. Expert opinion 96
Usually each regimen (except anthracyclines) should be given until progression of disease or
unacceptable toxicity.
1 B 72
What is considered unacceptable should be deﬁned together with the patient.
Other agents
Bevacizumab combined with a chemotherapy as 1st or 2nd line therapy for MBC provides only a moderate
beneﬁt in PFS and no beneﬁt in OS. The absence of known predictive factors for bevacizumab efﬁcacy renders
recommendations on its use difﬁcult. Bevacizumab can only therefore be considered as an option in selected
cases in these settings and is not recommended after 1st/2nd line.
1 A 74
Speciﬁc populations: treatment of metastatic male MBC
For ERþ Male MBC, which represents the majority of the cases, ET is the preferred option, unless there is
concern or proof of endocrine resistance or rapidly progressive disease needing a fast response.
Expert opinion 100
For ERþ Male MBC tamoxifen is the preferred option. Expert opinion 83
For male patients with MBC who need to receive an AI, a concomitant LHRH agonist or orchidectomy is the
preferred option. AI monotherapy may also be considered, with close monitoring of response.
Expert opinion 86
Clinical trials are needed in this patient population.
Speciﬁc sites of metastases
Bone metastases
Radiological assessments are required in patients with persistent and localized pain due to bone
metastases to determine whether there are impending or actual pathological fractures. If a fracture of a
long bone is likely or has occurred, an orthopaedic assessment is required as the treatment of choice may be
surgical stabilization, which is generally followed by RT. In the absence of a clear fracture risk, RT is the
treatment of choice.
1 A 96
Neurological symptoms and signs which suggest the possibility of spinal cord compression must be
investigated as a matter of urgency. This requires a full radiological assessment of potentially affected area
as well as adjacent areas of the spine. MRI is the method of choice. An emergency surgical opinion
(neurosurgical or orthopaedic) may be required for surgical decompression. If no decompression/stabilization
is feasible, emergency radiotherapy is the treatment of choice and vertebroplasty is also an option.
1 B 100
Brain metastases
Patients with a single or small number of potentially resectable brain metastases should be treated with
surgery or radiosurgery. Radiosurgery is also an option for some unresectable brain metastases.
1 B 92
If surgery/radiosurgery is performed it may be followed by whole brain radiotherapy but this should be
discussed in detail with the patient, balancing the longer duration of intracranial disease control and the
risk of neurocognitive effects.
1 B 72
Because patients with HER2þve MBC and brain metastases can live for several years, consideration of
long-term toxicity is important and less toxic local therapy options (e.g. stereotactic RT) should be preferred
to whole brain RT, when available and appropriate (e.g. in the setting of a limited number of brain metastases).
1 C 89
Liver metastases
Prospective randomized clinical trials of local therapy for BC liver metastases are urgently needed,
since available evidence comes only from series in highly selected patients. Since there are no randomized
data supporting the effect of local therapy on survival, every patient must be informed of this when discussing
a potential local therapy technique. Local therapy should only be proposed in very selected cases of good
performance status, with limited liver involvement, no extra-hepatic lesions, after adequate systemic therapy
has demonstrated control of the disease. Currently, there are no data to select the best technique for the
individual patient (surgery, stereotactic RT, intra-hepatic CT…).
Expert opinion 83
Malignant pleural effusions
Malignant pleural effusions require systemic treatment with/without local management. Thoracentesis
for diagnosis should be performed if it is likely that this will change clinical management. False negative
results are common. Drainage is recommended in patients with symptomatic, clinically signiﬁcant pleural
effusion. Use of an intrapleural catheter or intrapleural administration of talc or drugs (e.g. bleomycin, biological
response modiﬁers) can be helpful. Clinical trials evaluating the best technique are needed.
2 B 86
Chest wall and regional (nodal) recurrences
Due to the high risk of concomitant distant metastases, patients with chest wall or regional (nodal) recurrence
should undergo full restaging, including assessment of chest, abdomen and bone.
Expert opinion 100
Chest wall and regional recurrences should be treated with surgical excision when feasible with limited
risk of morbidity.
1 B 97
Locoregional radiotherapy is indicated for patients not previously irradiated. 1 B 97
For patients previously irradiated, re-irradiation of all or part of the chest wall may be considered in
selected cases.
Expert opinion 97
In addition to local therapy (surgery and/or RT), in the absence of distant metastases, the use of systemic
therapy (CT, ET and/or anti-HER-2 therapy) should be considered.
1 B 95
CT after ﬁrst local or regional recurrence improves long-term outcomes primarily in ER negative disease.
ET in this setting improves long-term outcomes for ER positive disease.
(continued on next page)
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Table 2 (continued )
Recommendations LoE % Consensus
The choice of systemic treatment depends on tumor biology, previous treatments, length of disease free
interval, and patient-related factors (co-morbidities and preferences).
In patients with disease not amenable to radical local treatment, the choice of palliative systemic
therapy should be made according to principles previously deﬁned for metastatic BC.
Expert opinion 97
These patients may still be considered for palliative local therapy.
Supportive and palliative care
Supportive care allowing safer and more tolerable delivery of appropriate treatments should always
be part of the treatment plan.
1 A 100
Early introduction of expert palliative care, including effective control of pain and other
symptoms, should be a priority.
1 A 100
Access to effective pain treatment (including morphine, which is inexpensive) is necessary for
all patients in need of pain relief.
1 A 100
Optimally, discussions about patient preferences at the end of life should begin early in the course
of metastatic disease. However, when active treatment no longer is able to control widespread and
life-threatening disease, and the toxicities of remaining options outweigh beneﬁts, physicians and
other members of the healthcare team should initiate discussions with the patient (and family
members/friends, if the patient agrees) about end-of-life care.
Expert opinion 96
ABC statements for LABC (Note: For the purpose of these recommendations, LABC means
inoperable, non-metastatic locally advanced breast cancer)
Before starting any therapy, a core biopsy providing histology and biomarker (ER, PR, HER-2,
proliferation/grade) expression is indispensable to guide treatment decisions.
1 B 97
Since LABC patients have a signiﬁcant risk of metastatic disease, a full staging workup, including a
complete history, physical examination, lab tests and imaging of chest and abdomen
(preferably CT) and bone, prior to initiation of systemic therapy is highly recommended.
1 B 100
PET-CT, if available, may be used (instead of and not on top of CTs and bone scan). 2 B 100
Systemic therapy (not surgery or RT) should be the initial treatment. Expert opinion 100
If LABC remains inoperable after systemic therapy and eventual radiation, ‘palliative’ mastectomy
should not be done, unless the surgery is likely to result in an overall improvement in quality of life.
A combined treatment modality based on a multidisciplinary approach (systemic therapy, surgery
and radiotherapy) is strongly indicated in the vast majority of cases.
1 A 100
For Triple Negative LABC, Anthracycline- and-taxane-based chemotherapy is recommended as initial treatment. 1 A 85
For HER-2 þ LABC, concurrent taxane and anti-HER-2 therapy is recommended since it increases the rate of pCR. 1 A 92
For HER-2 þ LABC, anthracycline-based chemotherapy should be incorporated in the treatment regimen. 1 A 72
When an anthracycline is given, it should be administered sequentially with the anti-HER-2 therapy. 1 A 87
Options for HR þ LABC include an anthracycline- and taxane-based chemotherapy regimen, or
endocrine therapy.
1 A 85
The choice of CT versus ET, as initial treatment, will depend on tumor (grade, biomarker expression)
and patient (menopausal status, performance status, comorbidities, preference) considerations.
Expert opinion 85
Following effective neoadjuvant systemic therapy with or without radiotherapy, surgery will be
possible in many patients. This will consist of mastectomy with axillary dissection in the vast majority
of cases, but in selected patients with a good response, breast conserving surgery may be possible.
2 B 98
Inﬂammatory LABC
For inﬂammatory LABC, overall treatment recommendations are similar to those for non-inﬂammatory
LABC, with systemic therapy as ﬁrst treatment.
1 B 93
Mastectomy with axillary dissection is recommended in almost all cases, even when there is good
response to primary systemic therapy.
I B 95
Immediate reconstruction is generally not recommended in patients with inﬂammatory LABC. Expert opinion 95
Loco-regional radiotherapy (chest wall and lymph nodes) is required, even when a pCR is achieved
with systemic therapy.
1 B 98
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Most clinical situations occur as a continuum and dividing them
into categories of stage, grade, risk group, or other factors is always
artiﬁcial and based on oversimpliﬁcation of thresholds. Such a
categorization is, however, useful to guide treatment choices, to
help assure adherence to guidelines and recommendations, and to
facilitate clinical research. Following the effort of previous editions,
ABC provides two additional deﬁnitions: ‘oligometastatic disease’
discussed above and the complex clinical situation of ‘multipleSection 3: HER-2 positive ABC.
Guideline statement
Anti-HER-2 therapy should be offered early (as 1st line) to all patients with HER-2þ A
contra-indications to the use of such therapy
For highly selected patients* with ERþ/HER-2þMBC, for whom ET is chosen over CT, ET
with anti-HER-2 therapy (either trastuzumab or lapatinib) since the combination p
without CT’) compared to ET alone. The addition of anti-HER-2 therapy to ET in the
survival beneﬁt but long-term follow-up was not collected in the available trials. In a
being directly compared with CT þ anti-HER2 therapy. (*see deﬁnition in text)chronic conditions’. The latter is becoming increasingly important
and more frequent in view of the aging of the population in general
and of cancer patients in particular. Managing advanced cancer, the
consequences of the disease and of the rapidly increasing number
and type of pharmacologic and non-pharmacologic interventions
in patients with several coexisting conditions is a major challenge.
Furthermore, these patients are systematically excluded from
clinical trials and hence available data, in particular regarding the
use of new agents in these situations, are scarce and eagerly
needed.LoE Consensus
BC, except in the presence of 1 A Voters: 43
Yes: 98% (42)
should be given in combination
rovides PFS beneﬁt (i.e. ‘time
1st line setting has not led to a
ddition, this strategy is currently




Guideline statement LoE Consensus
For patients with ERþ/HER-2þMBC, for whom CT þ anti-HER2 therapy was chosen as 1st line therapy and provided a
beneﬁt, it is reasonable to use ET þ anti-HER2 therapy as maintenance therapy, after stopping CT, although this
strategy has not been studied in randomized trials.
1 C Voters: 39
Yes: 79% (31)
Abstain: 10% (4)
Patients progressing on an anti-HER-2 therapy combined with a cytotoxic or endocrine agent should be offered
additional anti-HER-2 therapy with subsequent treatment since it is beneﬁcial to continue suppression of the HER-2
pathway. The optimal duration of anti-HER-2 therapy for MBC (i.e. when to stop these agents) is currently unknown.
1 B Voters: 43
Yes: 91% (39)
Abstain: 7% (3)
In patients achieving a complete remission, the optimal duration of maintenance anti-HER2 therapy is unknown and
needs to be balanced against treatment toxicity, logistical burden and cost. Stopping anti-HER2 therapy after several
years of sustained complete remission may be considered in some patients, particularly if treatment re-challenge is
available in case of progression.
Expert opinion Voters: 42
Yes: 93% (39)
No: 7% (3)
Patients who have received any type of (neo)adjuvant anti-HER-2 therapy should not be excluded from clinical trials for
HER-2þ MBC. These patients remain candidates for anti-HER-2 therapies.
1 B Voters: 40
Yes: 100%
In the 1st line setting, for HER-2þ MBC previously treated (in the adjuvant setting with DFI >12 months) or untreated
with trastuzumab, combinations of CT þ trastuzumab are superior to combinations of CT þ lapatinib in terms of PFS
and OS.
1 A Voters: 44
Yes: 95% (42)
Abstain: 5% (2)
The standard 1st line therapy for patients previously untreated with anti-HER-2 therapy is the combination of
CT þ trastuzumab and pertuzumab, because it has proven to be superior to CT þ trastuzumab in terms of OS in this
population.
1 A Voters: 42
Yes: 86% (36)
Abstain: 12% (5)
For patients previously treated (in the (neo)adjuvant setting) with anti-HER-2 therapy, the combination of
CTþ trastuzumab and pertuzumab is an important option for 1st line therapy. Few (88) of these patients were treated
in the Cleopatra trial and all with trastuzumab-free interval >12 months.
1 A Voters: 41
Yes: 76% (31)
Abstain: 22% (9)
There are currently no data supporting the use of dual blockade with trastuzumab þ pertuzumab and CT beyond
progression (i.e. continuing dual blockade beyond progression) and therefore this 3 drug regimen should not be given
beyond progression outside clinical trials.
1 A (against its use) Voters: 43
Yes: 86% (37)
Abstain: 9% (4)
In a HER-2þ MBC patient, previously untreated with the combination of CT þ trastuzumab þ pertuzumab, it is
acceptable to use this treatment after 1st line.
Expert opinion Voters: 37
Yes: 76% (28)
Abstain: 16% (6)
After 1st line trastuzumab-based therapy, T-DM1 provides superior efﬁcacy relative to other HER-2-based therapies in
the 2nd line (versus lapatinib þ capecitabine) and beyond (versus treatment of physician's choice).
1 A Voters: 42
Yes: 88% (37)
Abstain: 129% (5)
T-DM1 should be preferred in patients who have progressed through at least 1 line of trastuzumab-based therapy,
because it provides an OS beneﬁt.
However, there are no data on the use of T-DM1 after dual blockade with trastuzumab þ pertuzumab.
In case of progression on trastuzumab-based therapy, the combination trastuzumab þ lapatinib is a reasonable
treatment option for some patients. There are however, no data on the use of this combination after progression on
pertuzumab or T-DM1.
1 B Voters: 43
Yes: 84% (36)
Abstain: 12% (5)
All patients with HER-2þ MBC who relapse after adjuvant or any line metastatic anti-HER-2 therapy should be
considered for further anti-HER-2 therapy, except in the presence of contraindications. The choice of the anti-HER-2
agent will depend on country-speciﬁc availability, the speciﬁc anti-HER-2 therapy previously administered, and the
relapse free interval. The optimal sequence of all available anti-HER-2 therapies is currently unknown.
1 B Voters: 40
Yes: 86% (36)
Abstain: 12.5% (5)
Regarding the CT component of HER-2 positive MBC treatment: 1 A Voters: 41
Yes: 88% (36)
Abstain: 10% (4)
When pertuzumab is not given, 1st line regimens for HER-2MBC can include trastuzumab combinedwith vinorelbine or
a taxane. Differences in toxicity between these regimens should be considered and discussed with the patient in
making a ﬁnal decision.
Other CT agents can be administered with trastuzumab but are not as well studied and are not preferred.
For later lines of therapy, trastuzumab can be administered with several CT agents, including but not limited to,
vinorelbine (if not given in 1st line), taxanes (if not given in 1st line), capecitabine, eribulin, liposomal anthracyclines,
platinum, gemcitabine, or metronomic CM. The decision should be individualized and take into account different
toxicity proﬁles, previous exposure, patient preferences, and country availability.
2 A Voters: 43
Yes: 91% (39)
Abstain: 9% (4)
CT agents to combine with a dual blockade of trastuzumab þ pertuzumab are docetaxel (LoE: 1A) or paclitaxel (LoE: 1B).
Also possible are vinorelbine (LoE: 2 A), nab-paclitaxel (LoE: 2B) and capecitabine (LoE: 2A).
See in statement Voters: 43
Yes: 86% (37)
Abstain: 11.6% (5)
HER-2 þ ABC and brain metastases
In patients with HER-2-positive ABC with brain metastases and stable extracranial disease, systemic therapy should not
be changed.
1 C Voters: 42
Yes: 95% (40)
Abstain: 5% (2)
For patients with HER-2-positive cancers where brain metastases are the only site of recurrence, the addition of CT to
local therapy is not known to alter the course of the disease. It is recommended to re-start the anti-HER-2 therapy
(trastuzumab) if this had been stopped.
1 C Voters: 42
Y: 83% (35)
A: 7% (3)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; ET, endocrine therapy; CT, chemotherapy; DFI, disease-free
interval, CM, cyclophosphamide þ methotrexate.
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Among all breast cancer subtypes, HER2-positive ABC has had the
largest progress over the last decade. The introduction of new anti-
HER2 therapies, such as pertuzumab and T-DM1 [23e27], was a sig-
niﬁcant step forward but also created a number of new uncertainties
related to optimal combination/sequence of all available treatments.
In view of the overall survival (OS) results obtained with most
combinations of chemotherapy plus anti-HER-2 agents, the role of
endocrine therapy plus anti-HER-2 agents for the subgroup of pa-
tients with ERþ/HER-2þdisease has been questioned. Although
published studies have not demonstrated an OS beneﬁt of this
combination, long-term data were not collected in these trials. Of
note, the OS analysis of the TAnDEM trial, excluding patients who
crossed over to trastuzumab, demonstrated a borderline OS beneﬁt
for the combination arm [28]. In the absence of valuable bio-
markers, this approach should be reserved for highly selected pa-
tients, including those with contraindications to chemotherapy,
patient's with a strong preference against chemotherapy or those
with a long disease-free interval, minimal disease burden, in
particular in terms of visceral involvement, and/or strong ER/PgR
expression. Trials directly comparing chemotherapy plus anti-HER2
therapy versus endocrine therapy plus anti-HER2 therapy are
currently ongoing (Detect V/CHEVENDO (NCT02344472), SYSUCC-
002 (NCT01950182) and PERNETTA trials) and their results will
allow for better recommendations. In addition, in several countries
anti-HER2 therapy, namely trastuzumab, can only be used once in
the metastatic setting since its use beyond progression is either not
approved or not reimbursed; in those cases, preference should be
given to a combination of chemotherapy plus anti-HER-2 therapy.
The combination of endocrine therapy plus anti-HER2 therapy is
particularly useful as maintenance therapy for ERþ/HER2þABC,
after initial cycles of chemotherapy plus anti-HER-2 therapy.
Despite the absence of randomized trials, clinical experience and
low toxicity (in particular if trastuzumab is used), makes this a
reasonable option, most probably delaying disease progression and
the consequent need for chemotherapy.
The issue of duration of anti-HER-2 therapy in the metastatic
setting is of crucial importance, in view of the potential beneﬁts as
well as the substantial costs associated with these agents. There are
sufﬁcient data [29,30] to recommend continuing trastuzumab
beyond progression, but the optimal duration of this treatment and
how many lines beyond progression should it be used is currently
unknown. Data are very scarce related to the use beyond progres-
sion of other anti-HER2 agents and no data exist supporting the use
of dual blockade beyond progression.
A particularly difﬁcult situation, albeit also a fortunate one, re-
lates to the optimal duration of trastuzumab therapy in patients
achieving long-term complete remission. This needs to be balanced
against toxicity, logistical burden and cost. Currently no data exist
to support therapeutic decisions in this setting, and the panel
supported a cautious statement approving consideration of stop-
ping trastuzumab in these circumstances in some patients, partic-
ularly if treatment re-challenge is available in case of progression,
which is not the case in all countries.
Dual blockade with trastuzumab and pertuzumab in combina-
tion with chemotherapy as 1st line therapy, provides substantial
beneﬁt in terms of OS and PFS [23]. It is therefore considered by the
panel as the standard of care for patients previously untreated with
trastuzumab, in the (neo)adjuvant setting, and an important
treatment option for patients previously treated with trastuzumab.
The difference in the strength of recommendation is due to the fact
that very few patients (only 88) who were previously treated with
trastuzumab were enrolled in the Cleopatra trial. In addition, in the
Marianne trial [26] the dual blockade strategy did not prove to besuperior to chemotherapy and trastuzumab, albeit with a different
combination of agentsdT-DM1 and Pertuzumab. The reasons for
this lack of beneﬁt are currently unknown and could be related to
the different patient populations enrolled in both trials (more (30%)
patients in Marianne had been previously treated with trastuzu-
mab), the choice of agents with the presence or absence of syner-
gistic effects, the absence of standard chemotherapy agents (DM1
being a cytotoxic agent not used as single agent) or other factors.
After the discussion and voting during ABC3, the Pherexa [27]
study was presented, evaluating the role of dual blockade with
trastuzumab þ pertuzumab þ capecitabine for patients previously
treated with a taxane and trastuzumab in the metastatic setting.
Surprisingly, a non-signiﬁcant beneﬁt of only 2 months was seen in
the primary endpoint PFS, while an 8-month beneﬁt was observed
in OS albeit non-statistically signiﬁcant (in view of the lack of sig-
niﬁcant PFS beneﬁt).
Many questions remain unanswered in the management of
HER-2 þ ABC. We have no data on the role of dual blockade for
patients relapsing during and within 12 months of adjuvant tras-
tuzumab, since these patients have been excluded from clinical
trials. This aggressive situation is a clear unmet need for which data
must be generated. Following the approval, both by FDA and EMA,
of pertuzumab use in the neoadjuvant setting, there is an urgent
need to evaluate the best treatment options for the patients who
relapse after receiving chemotherapy þtrastuzumabþpertuzumab
in the early setting. It is also currently unknown how
trastuzumab þ pertuzumab þ chemotherapy compares to T-DM1,
as 1st or later lines of therapy. We also have no data on the best
treatment option after progression on dual blockade with pertu-
zumabþtrastuzumab, namely how T-DM1 performs in this setting.
While trastuzumab þ lapatinib (without chemotherapy) is a
valuable option for some patients, after progression on
chemotherapy þ trastuzumab, there are no data on the use of this
combination after progression on pertuzumab or T-DM1.
All these unanswered questions and the deﬁnition of the best
sequence of therapies for the individual patient may prove difﬁcult
to evaluate in prospective, randomized trials, with the absence of
speciﬁc biomarkers. In this scenario, registry studies, such as the
SystHERs Registry Study [31] and registHER, as well as collection of
treatment and outcome data beyond progression in all HER-2-
positive ABC clinical trials, are of great importance.
In ABC3, the optimal chemotherapy component for the treat-
ment of HER-2þdisease was discussed. The panel has stressed the
importance of treatment decisions that are based not only on ef-
ﬁcacy, but also on toxicity proﬁle, and patients' preferences.
For 1st line therapy, when trastuzumab is used as sole anti-Her2
agent, the preferred agents are vinorelbine or a taxane. Importantly,
single agent vinorelbine in association with trastuzumab has
shown superior or equal efﬁcacy compared to either paclitaxel or
docetaxel, in the TRAVIOTA and HERNATA trials, and has a better
tolerability [32,33]. For later lines of therapy, trastuzumab can be
administered with almost all chemotherapy agents, including but
not limited to, vinorelbine (if not given in 1st line), taxanes (if not
given in 1st line), capecitabine, eribulin, liposomal anthracyclines,
platinum, gemcitabine, or metronomic CM (low dose, oral, cyclo-
phosphamide and methotrexate). The decision should be individ-
ualized and take into account different toxicity proﬁles, previous
exposure, patient preferences, and country availability. Combina-
tions of other anti-HER2 agents, namely TKIs, with chemotherapy
are more limited due to toxicity. There are currently no data to
decide on the best sequence for each individual patient.
When dual blockade with trastuzumab and pertuzumab is used,
possible agents to combine are docetaxel [23], weekly paclitaxel
[34], vinorelbine [35] and nab-paclitaxel [36]. After the voting that
took place in ABC3, the Pherexa trial [27], presented at ASCO 2016,
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blockade with capecitabine.Section 4: ER positive/HER-2 negative (luminal) ABC.
Guideline statement LoE Consensus
Endocrine therapy (ET) is the preferred option for hormone receptor positive disease, even in the presence of visceral
disease, unless there is visceral crisis or concern/proof of endocrine resistance.
1 A Voters: 41
Yes: 93% (38)
Abstain: 7% (3)
The preferred 1st line ET for postmenopausal patients depends on type and duration of adjuvant ET as well as time
elapsed from the end of adjuvant ET; it can be an aromatase inhibitor, tamoxifen or fulvestrant.
1 A Voters: 44
Yes: 84% (37)
Abstain: 7% (3)
The combination of a nonsteroidal AI and fulvestrant as ﬁrst-line therapy for postmenopausal patients resulted in
signiﬁcant improvement in both PFS and OS compared to AI alone in one phase III trial and no beneﬁt in a second trial
with a similar design. Subset analysis suggested that the beneﬁt was limited to patients without prior exposure to
adjuvant ET (tamoxifen). Based on these data, combination ET may be offered to some patients with MBC without
prior exposure to adjuvant ET.




The addition of everolimus to an AI is a valid option for some postmenopausal patients with disease progression after a
non-steroidal AI, since it signiﬁcantly prolongs PFS, albeit without OS beneﬁt. The decision to treat must take into
account the individual relevant toxicities associated with this combination and should be made on a case by case
basis.
1 B Voters: 40
Yes: 84% (34)
Abstain: 13% (5)
Tamoxifen can also be combined with everolimus. 2 B
The addition of the CDK4/6 inhibitor palbociclib to an aromatase inhibitor, as 1st line therapy, for postmenopausal
patients (except patients relapsing <12 months from the end of adjuvant AI), provided a signiﬁcant improvement in
PFS (10 months), with an acceptable toxicity proﬁle, and is therefore one of the preferred treatment options, where
available. OS results are still awaited.




The addition of CDK4/6 inhibitor palbociclib to Fulvestrant, beyond 1st line therapy, for pre/peri/postmenopausal
patients, provided signiﬁcant improvement in PFS (~5 months) as well as improvement of QoL, and is a treatment
option. OS results are awaited.
1 A Voters: 42
Yes: 86% (36)
Abstain: 10% (4)
For pre/peri-menopausal pts, an LHRH-agonist must also be used.
At present, no predictive biomarker other than hormone receptor status exists to identify patients who will beneﬁt from
these type of agents and research efforts must continue.
ESMO MCBS: 4*
The optimal sequence of endocrine agents after 1st line ET is uncertain. It depends on which agents were used in the
(neo)adjuvant and 1st line ABC settings. Available options include AI, tamoxifen, fulvestrant þ palbociclib,
AI þ everolimus, tamoxifen þ everolimus, fulvestrant, megestrol acetate and estradiol.
1 A Voters: 40
Yes: 93% (37)
Abstain: 5% (2)
It is currently unknown how the different combinations of endocrine þ biological agents compare with each other, and
with single agent CT. Several trials are ongoing.
For pre-menopausal women, for whom ET was decided, ovarian suppression/ablation combined with additional
endocrine therapy is the preferred choice.
1 B Voters: 43
Yes: 93% (40)
Abstain: 5% (2)
Ovarian ablation by laparoscopic bilateral oophorectomy ensures deﬁnitive estrogen suppression and contraception,
avoids potential initial tumor ﬂare with LHRH agonist, and may increase eligibility for clinical trials.
Expert opinion Voters: 43
Yes: 91% (39)
Abstain: 7% (3)Patients should be informed on the options of OS/OA and decision should be made on a case by case.
For pre-menopausal women, the additional endocrine agent can be AI or tamoxifen, according to type and duration of
prior adjuvant endocrine therapy but AI absolutely mandates the use of ovarian suppression/ablation.
1 B Voters: 42
Y: 95% (40)
Abstain: 5% (2)Fulvestrant is also a valuable option, but for the moment also mandates the use of ovarian suppression/ablation. 1 C
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; ET, endocrine therapy; CT, chemotherapy; QoL, quality-of-life.
ESMO MBCS ¼ ESMO Magnitude of Clinical Beneﬁt Scale; OS/OA, ovarian suppression/ovarian ablation; * ¼ very important explanation in text.ER positive/HER-2 negative (Luminal) ABC
One of the most important recommendations relates to the
preferred treatment for luminal ABC, which should be endocrine
therapy in the majority of cases, excluding those with visceral crisis
and concern or proof of endocrine resistance. All breast cancer
guidelines concur with this recommendation but unfortunately
real life data studies show that most of these patients still receive
chemotherapy as their ﬁrst treatment, despite the lower efﬁcacy
[37].
Visceral crisis and endocrine resistance have been deﬁned
during ABC 2 and published [1]. However, better predictive factors
are urgently needed to clearly identify those patients whose tumors
have primary endocrine resistance and are responsible for the early
and rapid progression seen in ~20e25% of luminal ABC patients
treated with endocrine therapy [38]. Possible reasons may include
ER loss [39] or ER mutations [40].
The most important advance in the management of luminal ABC
over the last 2 years has undoubtedly been the introduction of anew class of agents, the CDK4/6 inhibitors, in combination with an
endocrine agent.The value of the CDK4/6 inhibitor palbociclib, combined with an
aromatase inhibitor as 1st line therapy was evaluated initially in a
randomized phase II study, the PALOMA 1 trial [41], which showed
a substantial 10-month beneﬁt in progression-free-survival (PFS)
coupled with a favorable toxicity proﬁle (main toxicity being neu-
tropenia). Based on these results, FDA granted accelerated approval,
which resulted in the drug being commercially available in USA. At
the 2016 ASCOmeeting, the phase III PALOMA 2 trial was presented
and conﬁrmed the 10-month beneﬁt in PFS, with the main toxic-
ities being hematological (mainly neutropenia) and fatigue [41]. OS
results are still awaited. In view of these results, the initial state-
ment developed at ABC3 was modiﬁed and re-voted by email and
considers this option as one of the preferred treatment options,
where available. Very recently (September 2016) EMA also started
the approval process of Palbociclib. However, its approval/reim-
bursement in all individual countries is still pending and the issue
of cost is of crucial importance for its implementation in clinical
practice, as it is for many targeted agents namely anti-HER-2
agents.
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fulvestrant resulted in signiﬁcant albeit lower 5-month PFS pro-
longation in the PALOMA 3 phase III trial [42]. The quality of life
substudy has shown both an overall improvement and a delayed
deterioration of this important endpoint, with greater improve-
ment in baseline pain, in the palbociclib arm [43]. Importantly, the
PALOMA-3 study accrued both postmenopausal and pre/perimen-
opausal (in combination with ovarian function suppression) pa-
tients, allowing for assessment of the drug efﬁcacy in a breast
cancer population usually excluded from ABC endocrine therapy
trials. OS results are still awaited. In view of available results, theSection 5: triple negative ABC.
Guideline statement LoE Consensus
For non-BRCA-associated triple negative ABC, there are no data supporting different or speciﬁc CT recommendations.
Therefore, all CT recommendations for HER-2 negative disease also apply for triple negative ABC.
1 A Voters: 44
Yes: 98% (43)
Abstain: 2% (1)
In triple-negative ABC patients (regardless of BRCA status), previously treated with anthracyclines with or without
taxanes in the (neo)adjuvant setting, carboplatin demonstrated comparable efﬁcacy and a more favorable toxicity
proﬁle, compared to docetaxel, and is therefore an important treatment option.
1 A Voters: 43
Yes: 91% (39)
Abstain: 5% (2)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; CT, chemotherapy.ABC panel considers this as a treatment option, where available.
The ESMO Magnitude of Clinical Beneﬁt Scale (MCBS) was
calculated for the recently approved Palbociclib, for use in 1st line
and in 2nd line. As a reminder, the MCBS scores a given treatment
in a given setting, and based on published trials. At the time of
publishing the ABC3 guidelines, PALOMA 2 main results and the
accompanying quality of life substudy have been presented but not
yet published. For this reason, the MCBS for the use of palbociclib in
1st line was calculated using the PALOMA 1 trial efﬁcacy data,
which scores a 3 for efﬁcacy. Once the PALOMA 2 data is published
theMCBSwill be updatedwith an e-update made available through
the ESMO guidelines website. For the use of palbociclib as 2nd line
therapy, data from PALOMA 3, both efﬁcacy and quality of life, were
used. The MCBS was 3 for efﬁcacy, and due to the improvement in
quality of life upgraded to 4, which is the ﬁnal score for this setting.
Another possible therapy is the combination of endocrine
therapy with the mTOR inhibitor, everolimus. This combination has
shown a PFS beneﬁt of ~6 months, without a signiﬁcant OS beneﬁt,
andwith signiﬁcant toxicity [44,45]. However, as withmany agents,
as more experience is gained regarding the use of everolimus and
the management of its toxicities, its clinical use becomes easier. In
addition, patient education is fundamental for prevention and early
management of associated side effects. Of particular attention is the
possibility of an excess mortality of this combination in elderly
patients (>70 years of age) [44,46].
Currently, and in spite of intensive research, no predictive
biomarker, other than hormone receptor status, exists to identify
patients who will beneﬁt the most from either m-TOR or CDK4-6
inhibitors and research efforts must continue.
The panel did not support (53.4% against) the 1st line combi-
nation of non-steroidal aromatase inhibitor and fulvestrant based
on the results of the SWOG S0226 trial [47]. There may be a beneﬁt
for the minority of postmenopausal patients who are endocrine-Section 6: other recommendations.
Guideline statement
Chemotherapy other
Metronomic chemotherapy is a reasonable treatment option, for patients not requiri
better studied regimen is CM (low dose oral cyclophosphamide and methotrexate);
evaluated (including capecitabine and vinorelbine). Randomized trials are needed to
CT with standard dosing regimens.naïve.
The deﬁnition of the best 1st line approach for postmenopausal
patients will soon have additional data through the phase III FAL-
CON data that will be presented this year.
The optimal sequence of single endocrine agents and combi-
nations with targeted agents is currently unknown and is a
research priority. It is crucial to collect data from clinical trials
beyond progression to better understand the efﬁcacy of each class
of agent when given after the other (e.g. CDK4-6 inhibitors after m-
TOR inhibitors and vice-versa).Triple negative ABC
The treatment of triple-negative breast cancer (TN-ABC) still
remains the largest unmet need within ABC. In spite of extensive
research, no treatments apart from chemotherapy have so far
proven to be effective for this population. For this reason, no spe-
ciﬁc recommendations can be made for this ABC subtype, with the
possible exception of platinum compounds for BRCA-mutated
patients.
Probably the largest achievement of the last 2 years was the TNT
study, comparing ‘standard’ docetaxel to carboplatin in unselected
TNBC patients (with pre-speciﬁed subgroup analysis of BRCA-
mutation carriers). The superiority of carboplatin was demon-
strated only among BRCA-positive patients, while in the unselected
TN-ABC population docetaxel and carboplatin seem to have a
similar efﬁcacy [48], although the study was not designed as a non-
inferiority study. Of note, in this study, 15% of patients had no prior
adjuvant chemotherapy and only 35% had received (neo)adjuvant
taxanes. Importantly, due to the signiﬁcantly better toxicity proﬁle
of carboplatin, it remains an attractive treatment choice even for
unselected TN-ABC patients. Unfortunately, other putative predic-
tive factors of increased sensitivity to platinum, such as homolo-
gous recombination deﬁcit (HRD) and the basal-like Prosigna
PAM50 signature were not proven of value for making treatment
decisions in this setting.
The future of TN-ABC treatment seems to lie in a better bio-
logical characterization of this breast cancer subtype into further
subgroups, followed by the development of speciﬁc therapies for
each of the subgroups. An example is the Luminal AR subtype,
characterized by the expression of the androgen receptor; anti-
androgens have recently demonstrated some activity and are being
further evaluated, and where a potential predictive marker, the
Predict AR assay, is also being tested [49,50].LoE Consensus
ng rapid tumor response. The
other regimens are being
accurately compare metronomic




Guideline statement LoE Consensus
Even if given in the adjuvant setting, provided that cumulative dose has not been achieved and that there are no cardiac
contra-indications, anthracyclines can be re-used in MBC, particularly if there has been at least 1 year of disease-free
survival.




In patients with BRCA-associated triple negative or endocrine-resistant MBC previously treated with an anthracycline
with or without a taxane (in the adjuvant and/or metastatic setting), a platinum regimen is the preferred option, if not
previously administered and no suitable clinical trial is available.
1 A Voters: 44
Yes: 86% (38)
Abstain: 9% (4)
In patients with TN or Luminal MBC, genetic counseling and possibly BRCA testing should be discussed with the
patient, if the results can impact on treatment decisions and/or on clinical trials entry.




A bone modifying agent (bisphosphonate, denosumab) should be routinely used in combination with other systemic
therapy in patients with MBC and bone metastases.
1 A Voters: 44
Yes: 95% (42)
Abstain: 5% (2)Three-monthly zolendronic acid seems to be not inferior to standard monthly schedule. 1 B
Supplementation of calcium and vitamin D3 is mandatory, unless contraindications exist. 1 C
Otherdbiomarkers
Multigene panels, such as those obtained using next generation sequencing (NGS) or other technology, regarding
evolving molecular changes in ABC tumors has not yet proven beneﬁcial in clinical trials, their impact on outcome
remains undeﬁned and should only be considered investigational.
1 C Voters: 44
Yes: 95% (42)
Abstain: 5% (2)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; MBC, metastatic breast cancer.
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Several options exist for chemotherapy both for ﬁrst and sub-
sequent lines of therapy. The ABC panel maintains that for patients
pretreated with anthracyclines and taxanes the preferred agents,
based on their efﬁcacy and toxicity proﬁle, are capecitabine,
vinorelbine and eribulin. The latter is one of the few agents to
provide a survival gain, albeit small (2.5 months) in a heavily pre-
treated population of ABC patients [51]. In a head-to-head com-
parison between eribulin and capecitabine, as ﬁrst or second line
therapy, there were no major differences between the drugs in
efﬁcacy but a different toxicity proﬁle [52].
It is also possible to re-challenge with anthracyclines, particu-
larly if there has been at least 1 year of disease-free survival, and if
the cumulative dose has not been reached, a common situation
nowadays because of the lower doses of anthracyclines used in the
adjuvant setting. Re-challenge with taxanes is also possible, pro-
vided that there has been at least 1 year of disease-free survival.
Another very attractive option is the use of metronomic
chemotherapy, deﬁned as the use of low doses and short intervals,
which has been evaluated in the advanced setting with interesting
efﬁcacy results and an excellent toxicity proﬁle [53]. The best
evaluated regimen is oral cyclophosphamide and oral methotrexate
but other agents are being studied such as vinorelbine and
capecitabine.
In view of the lack of substantial efﬁcacy differences among the
different available options, their toxicity proﬁle must be discussedSection 7: Supportive and palliative care.
Guideline statement
Management of CANCER RELATED FATIGUE
Cancer related fatigue is frequently experienced by patients with ABC, exerts a deleter
functional, psychological and social well-being. The etiology of this fatigue is compl
multidimensional. It is important to assess it using appropriate PRO measures befor
pharmacological (such as exercisedLoE: 1 A) and if needed pharmacological interv
Management of CDK Inhibitor Induced Neutropenia
Neutropenia is the most common toxicity associated with CDK 4/6 inhibition and is n
neutropenia although an increase in infections has been reported. Treatment should
recovered to at least 1000/ìl; dose reduction can also be considered.
Management of Non-Infectious Pneumonitis (NIP)
NIP is an uncommon complication of mTOR inhibition. Patient education is critical to
symptoms.
Treatment interruption and dose reduction are generally effective for grade 2 symptoma
treatment discontinuation for grade 3 or greater toxicity.with the patient and her/his preferences taken into account.
ABC3 also further endorsed the use of bone-modifying agents
(bisphosphonate, denosumab) in combination with
calcium þ vitamin D3 supplementation as a routine component of
management of patients with bone metastases. Denosumab has
demonstrated slightly better efﬁcacy and better tolerability,
compared to zoledronic acid [54], having the advantage of a sub-
cutaneous route of administration and the disadvantage of a sub-
stantially higher cost in most countries; where available, it can be
considered a preferred option. Currently available data support
replacing routine 4 weekly administration of intravenous
bisphosphonates by 3-monthly zoledronic acid after an initial
period of monthly use [55,56]. Early 3-monthly use seems associ-
ated with increased need for major surgeries [57], so a reasonable
compromise may be to start with the monthly schedule for the ﬁrst
year and then change to 3-monthly regimen. No data exist on the
optimal overall treatment duration of bone modifying agents, and
their efﬁcacy must be weighed against long-term toxicity (such as
osteonecrosis of the jaw and atypical fractures).
When a bone modifying agent is given, supplements of calcium
and vitamin D are mandatory, except in the presence of contra-
indications.
Unfortunately, nomultigene testing technology has been proven
to be beneﬁcial in supporting treatment choices in ABC patients
[18] and the panel strongly discourages their use in clinical practice.
They should continue to be considered investigational.LoE Consensus
As in the text 100%
ious impact on QoL and limits physical,
ex so effective management needs to be
e implementing various non-
entions (LoE: 2 B).
2 A 100%
ot generally associated with febrile
be delayed until neutrophils have
2 A 100%
ensure early reporting of respiratory
tic NIP with use of systemic steroids and
(continued on next page)
(continued )
Guideline statement LoE Consensus
Management of MUCOSITIS/STOMATITIS 100%
Mild toothpaste and gentle hygiene are recommended for the treatment of stomatitis. Early intervention is recommended. For
grade 2 or higher stomatitis, delaying treatment until the toxicity resolves and considering lowering the dose of the targeted
agent are also recommended. Consider adding steroid dental paste to treat developing ulcerations.
Expert opinion
Steroid mouthwash can be used for prevention of stomatitis (suggested schedule: 0.5 mg/5 ml dexamethasone, 10 ml to
swish  2 min then spit out qid).
1 B
Management of DYSPNEA As in the text 100%
Treatable causes like pleural effusion, pulmonary emboli, cardiac insufﬁciency, anemia or drug toxicity must be ruled out. Patient
support is essential. Oxygen is of no use in non-hypoxic patients. Opioids are the drugs of choice in the palliation of dyspnea
(LoE: 1 A). Benzodiazepines can be used in patients experiencing anxiety (LoE: 2A). Steroids can be effective in dyspnea caused
by lymphangitis carcinomatosis, radiation or drug-induced pneumonitis, superior vena cava syndrome, an inﬂammatory
component, or in (cancer-induced) obstruction of the airways (in which case laser/stent is to be considered).
Management of NAUSEA and VOMITING Expert opinion 100%
ESMO/MASCC GUIDELINES are available for management of chemotherapy-induced and morphine-induced nausea and
vomiting, and these are endorsed by ABC3.
There is a need to study nausea and vomiting related to chronic use of anticancer drugs.
Management of endocrine toxicities of mTOR inhibition 2 A 100%
Hyperglycemia and hyperlipidemia are common sub-acute complications of mTOR inhibition. Evaluation of preexisting diabetes
or hyperglycemia at baseline is essential. Regular careful monitoring of glycemia and lipid panel is needed to identify these
toxicities.
Management of grade 1 and 2 hyperglycemia include treatment with oral antidiabetics and basal insulin, in accordance with
international recommendation for diabetes mellitus treatment. Statins are indicated to treat grade 2 and 3
hypercholesterolemia, and ﬁbrates should be introduced if triglyceride level >500 mg/dl (with attention to possible drug
edrug interaction between everolimus and ﬁbrates). Treatment interruption and dose reduction are generally effective for
grade 2 and 3. Treatment should be discontinued for grade 4 toxicity.
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; QoL, quality of life.
Note: The statements of this section were not voted during the ABC Consensus panel but were developed and agreed upon by email, by all panel members.
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The ABC panel decided to dedicate several recommendations to
the management of disease and treatment-related symptoms, a
problem faced daily by patients and every practicing oncologist,
that can signiﬁcantly affect a patient's quality of life.
Unfortunately, little high-quality data exist in many areas of
symptom management, probably due to difﬁculties in conducting
research in this ﬁeld, including the lack of well-deﬁned endpoints,
of patient-reported symptoms and side effects, and of optimal tools
to evaluate impact on quality of life for advanced cancer patients.
New classes of drugs introduced into breast cancer management
have brought into the clinical practice new toxicities, poorly un-
derstood in the beginning and unfamiliar to most oncologists.
Undoubtedly this is an area of unmet need, which should be a
research priority.
The ABC3 guidelines provide guidance on the management of
drug-induced pneumonitis, mucositis [58,59], endocrine and
metabolic disorders and CDK4/6 inhibitor-related neutropenia. For
nausea and vomiting ABC fully endorses the guidelines developed
by ESMO/MASCC [60].
The ABC panel continues to discuss and provide guidance on the
management of frequent and difﬁcult to manage cancer-associated
symptoms. In this edition, dyspnea and fatigue were discussed.
Cancer related fatigue is frequently experienced by advanced can-
cer patients, exerts a deleterious impact on their quality of life and
limits physical, functional, psychological and social well-being. Its
etiology is complex and therefore effective management needs to
be multidimensional [61e63]. It is important to assess cancer
related fatigue using appropriate patient-reported outcome mea-
sures before implementing various pharmacological and non-
pharmacological interventions. Randomized studies have sug-
gested improvement of fatigue by various types of exercise quite
convincingly [64], and meditation and some pharmacologic in-
terventions are under evaluation. The use of good evidence-based
algorithms for management of cancer related fatigue can also be
helpful [65].Conclusions
Since the ABC3 Conference two important initiatives have
already been initiated.
The ESMO Magnitude of Clinical Beneﬁt Scale (MCBS) [8] has
been published and is being applied to all new anticancer treat-
ments approved by EMA. The latest drug for which EMA started the
approval process was Palbociclib in September 2016 and its MCBS
evaluation is included in the present article. Should another agent
be approved before the next ABC Consensus Conference, the ESMO
Committees will apply the MCBS and the result will be made
available as an e-update to the present guidelines.
Following on the success of the ABC Consensus Conference, the
ABC community has come together to create the ABC Global
Alliance. This Alliance will function as a platform where all
involved partners (advocacy groups, pharma, cooperative groups,
societies, individuals) will be able to work together, in projects
designed to improve the lives of ABC patients. The Global Status of
ABC Decade Report [2] has highlighted several areas of unmet
needs. Based on these ﬁndings, a global Call-To-Action is being
developed, with tangible objectives that need to be achieved
within the next decade to meaningfully impact the outcomes of
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